Biography
Research Topics
Multi-Disciplinary Training Area
Merle (Menachem) Fromer, PhD
ADJUNCT ASSOCIATE PROFESSOR | Psychiatry
ADJUNCT ASSOCIATE PROFESSOR | Psychiatry
Research
The current focus of Menachem’s research is in developing computational tools to analyze (exome) sequencing data of large samples of thousands of schizophrenia patients in order to uncover genetic variation, in particular structural variation. His main projects include detecting copy number variation (XHMM software) from exome resequecing data, in addition to sequencing-based phasing of haplotype information. Furthermore, he is studying schizophrenia trios (proband and parents) that are being exome sequenced to discover de novo coding mutations ranging from single-nucleotide variants, insertions/deletions, and copy number variation. He is also collaborating with a number of researchers on developing novel tools for integrating genetic findings into known biological pathways and other functional data, for example, protein-protein interaction networks and protein family and domain information.
Office Locations
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Fromer during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- VidaVinci
Outside Employment
- Johnson & Johnson
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Fromer during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- VidaVinci
Outside Employment
- Johnson & Johnson
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.